AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/08/astrazeneca-plc-azn-q4-2023-earnings-call-transcri/?source=iedfolrf0000001
Feb 08, 2024 - AZN earnings call for the period ending December 31, 2023.
0
Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
https://www.zacks.com/stock/news/2223659/astrazeneca-azn-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2223659
Feb 08, 2024 - Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM
https://www.zacks.com/stock/news/2223512/jobless-claims-steady-mixed-q4-for-azn-hsy-and-pm?cid=CS-ZC-FT-ahead_of_wall_street-2223512
Feb 08, 2024 - We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.
0
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2220303/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2220303
Feb 02, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
0
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
https://www.zacks.com/stock/news/2213681/will-the-individual-ma-unit-aid-humana-s-hum-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213681
Jan 22, 2024 - Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
0
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
https://www.zacks.com/commentary/2212742/top-research-reports-for-microsoft-procter-gamble-astrazeneca?cid=CS-ZC-FT-research_daily-2212742
Jan 19, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).
0
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
https://www.zacks.com/stock/news/2209409/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2209409
Jan 12, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
0
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2206582/astrazeneca-azn-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2206582
Jan 05, 2024 - The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.
0